Loading
Every dated change on the records linked to Primary mediastinal (thymic) large B-cell lymphoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Objective response rate 45%, complete response 13%, in 53 patients with relapsed or refractory disease; FDA accelerated approval June 2018.
A milestone in how this cancer is treated.
High objective and complete response rates in refractory large B-cell lymphoma with durable remissions in a large minority; approved in October 2017.
A milestone in how this cancer is treated.